Literature DB >> 25276405

The evolution of colorectal cancer genetics-Part 1: from discovery to practice.

Andrew T Schlussel1, Ronald A Gagliano1, Susan Seto-Donlon1, Faye Eggerding1, Timothy Donlon1, Jeffrey Berenberg1, Henry T Lynch1.   

Abstract

Colorectal cancer (CRC) is an increasing burden on our society. Identifying those who are at the greatest risk and improving triage for treatment will have the greatest impact on healthcare. CRC is a prime paradigm for cancer genetics: the majority of disease results from stages of progression lending itself to prevention by early detection of the pre-disease (neoplastic) state. Approximately 10% represent well defined hereditary cancer syndromes. Hereditary CRC has the added benefit that many are slow growing and family members are armed with the knowledge of potential risk of associated carcinomas and empowerment to reduce the disease burden. This knowledge provides the indication for early endoscopic and/or surgical intervention for prevention or treatment of an entire family cohort. The molecular basis of CRC allows enhanced characterization of carcinomas, leading to targeted therapies.

Entities:  

Keywords:  CRC syndromes; Colorectal cancer (CRC); Lynch syndrome (LS); genetics; prevention

Year:  2014        PMID： 25276405      PMCID： PMC4173047          DOI： 10.3978/j.issn.2078-6891.2014.069

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  59 in total

Review 1.  Testing guidelines for hereditary non-polyposis colorectal cancer.

Authors:  Asad Umar; John I Risinger; Ernest T Hawk; J Carl Barrett
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

2.  Differential diagnosis of hereditary nonpolyposis colorectal cancer (Lynch syndrome I and Lynch syndrome II).

Authors:  H T Lynch; P Watson; M Kriegler; J F Lynch; S J Lanspa; J Marcus; T Smyrk; R J Fitzgibbons; G Cristofaro
Journal:  Dis Colon Rectum       Date:  1988-05       Impact factor: 4.585

Review 3.  The role of aspirin in cancer prevention.

Authors:  Michael J Thun; Eric J Jacobs; Carlo Patrono
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

Review 4.  Epigenetic mechanisms in the pathogenesis of Lynch syndrome.

Authors:  P Peltomäki
Journal:  Clin Genet       Date:  2014-02-17       Impact factor: 4.438

5.  Modulation of mismatch repair and genomic stability by miR-155.

Authors:  Nicola Valeri; Pierluigi Gasparini; Muller Fabbri; Chiara Braconi; Angelo Veronese; Francesca Lovat; Brett Adair; Ivan Vannini; Francesca Fanini; Arianna Bottoni; Stefan Costinean; Sukhinder K Sandhu; Gerard J Nuovo; Hansjuerg Alder; Roberta Gafa; Federica Calore; Manuela Ferracin; Giovanni Lanza; Stefano Volinia; Massimo Negrini; Michael A McIlhatton; Dino Amadori; Richard Fishel; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

6.  Screening practices of unaffected people at familial risk of colorectal cancer.

Authors:  Driss Ait Ouakrim; Alex Boussioutas; Trevor Lockett; Ingrid Winship; Graham G Giles; Louisa B Flander; Louise Keogh; John L Hopper; Mark A Jenkins
Journal:  Cancer Prev Res (Phila)       Date:  2011-10-26

7.  Localization of the gene for familial adenomatous polyposis on chromosome 5.

Authors:  W F Bodmer; C J Bailey; J Bodmer; H J Bussey; A Ellis; P Gorman; F C Lucibello; V A Murday; S H Rider; P Scambler
Journal:  Nature       Date:  1987 Aug 13-19       Impact factor: 49.962

8.  Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer.

Authors:  Heather Hampel
Journal:  J Natl Compr Canc Netw       Date:  2010-05       Impact factor: 11.908

9.  Value of database linkage: are patients at risk of familial colorectal cancer being referred for genetic counselling and testing?

Authors:  C Wong; P Gibbs; J Johns; I Jones; I Faragher; E Lynch; F Macrae; L Lipton
Journal:  Intern Med J       Date:  2007-10-03       Impact factor: 2.048

10.  Knowledge about hereditary nonpolyposis colorectal cancer; mutation carriers and physicians at equal levels.

Authors:  Katarina Domanska; Christina Carlsson; Pär-Ola Bendahl; Mef Nilbert
Journal:  BMC Med Genet       Date:  2009-03-26       Impact factor: 2.103
View more
  9 in total

1.  Rectal cancer: a truly multidisciplinary challenge.

Authors:  Timothy D Wagner
Journal:  J Gastrointest Oncol       Date:  2014-10

2.  Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.

Authors:  Bryce A Seifert; Julianne M O'Daniel; Krunal Amin; Daniel S Marchuk; Nirali M Patel; Joel S Parker; Alan P Hoyle; Lisle E Mose; Andrew Marron; Michele C Hayward; Christopher Bizon; Kirk C Wilhelmsen; James P Evans; H Shelton Earp; Norman E Sharpless; D Neil Hayes; Jonathan S Berg
Journal:  Clin Cancer Res       Date:  2016-04-15       Impact factor: 12.531

3.  Gatekeeper role of gastroenterologists and surgeons in recognising and discussing familial colorectal cancer.

Authors:  Kirsten F L Douma; Evelien Dekker; Ellen M A Smets; Cora M Aalfs
Journal:  Fam Cancer       Date:  2016-04       Impact factor: 2.375

Review 4.  Opportunities for immunotherapy in microsatellite instable colorectal cancer.

Authors:  Harm Westdorp; Felix L Fennemann; Robbert D A Weren; Tanya M Bisseling; Marjolijn J L Ligtenberg; Carl G Figdor; Gerty Schreibelt; Nicoline Hoogerbrugge; Florian Wimmers; I Jolanda M de Vries
Journal:  Cancer Immunol Immunother       Date:  2016-04-08       Impact factor: 6.968

5.  Development of a new analog of SGK1 inhibitor and its evaluation as a therapeutic molecule of colorectal cancer.

Authors:  Xuchun Liang; Chunling Lan; Jinzhe Zhou; Wencheng Fu; Xuesha Long; Yu An; Guanming Jiao; Kejin Wang; Yongqin Li; Jiahong Xu; Qi Huang; Bin Xu; Junjie Xiao
Journal:  J Cancer       Date:  2017-07-20       Impact factor: 4.207

6.  An E-Learning Module to Improve Nongenetic Health Professionals' Assessment of Colorectal Cancer Genetic Risk: Feasibility Study.

Authors:  Kirsten Freya Lea Douma; Cora M Aalfs; Evelien Dekker; Pieter J Tanis; Ellen M Smets
Journal:  JMIR Med Educ       Date:  2017-12-18

7.  In Vivo Anti Cancer Potential of Pyrogallol in Murine Model of Colon Cancer.

Authors:  Seemaisamy Revathi; Faruck Lukmanul Hakkim; Neelamegam Ramesh Kumar; Hamid A Bakshi; Alagar Yadav Sangilimuthu; Murtaza M Tambuwala; Mohammad Changez; Muthukalingan Krishnan; Nagarajan Kayalvizhi
Journal:  Asian Pac J Cancer Prev       Date:  2019-09-01

Review 8.  Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type profiling and chemoresistance.

Authors:  Alfred Buhagiar; Elisa Seria; Miriana Borg; Joseph Borg; Duncan Ayers
Journal:  Cancer Drug Resist       Date:  2021-10-26

9.  Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.

Authors:  E Sanchez-Lopez; E Flashner-Abramson; S Shalapour; Z Zhong; K Taniguchi; A Levitzki; M Karin
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.